
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson is positioned favorably because its post-separation portfolio is now a more focused pure-play MedTech platform, with Medical Essentials, Connected Care, Biopharma Systems, and Interventional supported by a durable U.S.-centric base and more than 60% of revenue from the United States. The company’s outlook is strengthened by recurring demand, a +90% consumables revenue mix, and exposure to a $70B TAM growing at about 5%, while BD Excellence should keep lifting productivity, quality, and margins toward ~30% over time. Additional upside comes from the $18B Waters-related transaction, ~39% ownership, ~$345MM of annualized EBITDA synergies, and disciplined capital allocation, including ~$4B in cash proceeds, FY25 shareholder returns of about $2.2B, and buybacks as the top priority.
Bears say
Becton Dickinson is facing a weaker fundamental setup as the separation-driven “new BD” must still prove it can sustain growth while absorbing business investments, tariff pressure, and potential M&A dilution, even after benefits from BD Excellence. China remains a significant risk, with accelerating headwinds from VBP and the possibility that ongoing pressures could extend into FY26, while Alaris is expected to become a 200bp organic growth headwind in FY27 and create roughly 60bp of margin pressure as sales fall from about $500M to $100M. Although FQ4 revenue rose to $5,274M and EPS reached $4.15, the stock’s 16x NTM P/E looks demanding for a low-to-mid single-digit grower with limited pricing power and heavy U.S. concentration, making the downside case more compelling.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Becton, Dickinson and Co. (BDX) Forecast
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares